(Q36775615)

16 August 2017

1 reference

title

Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers (English)

1 reference

16 August 2017

0 references

1 reference

John J Lima

1

1 reference

16 August 2017

publication date

1 January 2007

1 reference

Molecular Diagnosis and Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

11

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

97-104

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256228

16 August 2017

exact match

0 references

cites work

The pharmacogenetics of asthma: a candidate gene approach

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Trends in pharmacogenomics of drugs used in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pharmacogenetic approaches in the treatment of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pharmacological management of mild or moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

The role of leukotrienes in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Effects of montelukast and beclomethasone on airway function and asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Influence of leukotriene pathway polymorphisms on response to montelukast in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Effect of montelukast on time‐course of exhaled nitric oxide in asthma: Influence of LTC4 synthase A−444C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Uncertain biologic relevance of polymorphisms of leukotriene C4 synthase in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Montelukast: a review of its therapeutic potential in persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pharmacokinetic profile of zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pranlukast: a review of its use in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Transporters and drug discovery: why, when, and how.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Role of organic cation transporters in drug absorption and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Role of transport proteins in drug absorption, distribution and excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pharmacogenomics of the OATP and OAT families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

A population pharmacokinetic model for montelukast disposition in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Molecular characterization and inhibition of amanitin uptake into human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Leukotriene modifiers as potential therapeutics for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256228

Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics

21 January 2018

1 reference

12 December 2020

Overview of the pharmacogenetics of asthma treatment.

1 reference

12 December 2020

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

1 reference

12 December 2020

Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers

1 reference

12 December 2020

The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma

1 reference

12 December 2020

Chemistry and structure--activity relationships of leukotriene receptor antagonists

1 reference

12 December 2020

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

1 reference

12 December 2020

The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.

1 reference

12 December 2020

Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.

1 reference

12 December 2020

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

12 December 2020

Pharmacokinetics of zileuton and its metabolites in patients with renal impairment

1 reference

12 December 2020

Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma

1 reference

12 December 2020

Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans

1 reference

12 December 2020

The common variants/multiple disease hypothesis of common complex genetic disorders

1 reference

12 December 2020

The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers

1 reference

12 December 2020

Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends.

1 reference

12 December 2020

Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile

1 reference

12 December 2020

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

12 December 2020

Decreases in Hispanic and non-Hispanic asthma mortality

1 reference

12 December 2020

In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256228

1 reference

16 August 2017

1 reference